Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

McKesson Corp Add to portfolio

INX:MCK, Sep 25, 09:53 UTC

Latest INX:MCK News

Filter your feed

Apply Filter

Yesterday


News

McKesson Medical-Surgical and ILÚM Health Solutions Announce Distribution Alliance in Community Hospital Market

MCK MRK

McKesson recognizes the strategic importance of innovative technology in the health care continuum, and has steadily accelerated its investment and growth in laboratory diagnostics over the past several years. “Through this alliance, we aim to help community hospitals overcome challenges related to the development and execution of effective antibiotic stewardship programs,” said Paul Edwards, managing director, ILÚM Health Solutions. “Studies show that the rate of antibiotic use in community hospitals is on par with academic medical centers.i This underscores the need for a technology solution that unlocks electronic patient data in order to help community hospitals maximize resources, meet national standards, and improve patient care.”. “We’re excited to partner with ILÚM and help represent its industry-leading dedicated Antimicrobial Stewardship Program (ASP) technology in the community hospital market,” said Doug Shaver, senior vice-president and general manager, McKesson Laboratory Solutions.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Sunday, September 23


News

EPS for McKesson Corporation (MCK) Expected At $3.28

MCK

It is positive, as 39 investors sold McKesson Corporation shares while 261 reduced holdings. Vantage Invest Advsr Limited Co owns 0.01% invested in McKesson Corporation (NYSE:MCK) for 275 shares. Tompkins Fincl Corporation has 0.02% invested in McKesson Corporation (NYSE:MCK). Since May 30, 2018, it had 0 insider purchases, and 4 sales for $644,452 activity. Analysts expect McKesson Corporation (NYSE:MCK) to report $3.28 EPS on October, 25.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $3.28 EPS.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Friday, September 21


News

Global Healthcare IT Market 2018-2022 with General Electric, IBM, McKesson Corporation, Koninklijke Philips & Siemens Dominating - ResearchAndMarkets.com

SIE IBM +2 more SIE IBM MCK GE

The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Investing in IT hardware and software tools has reduced the workload for doctors and support staff which has helped to improve the quality of treatment. Further, the report states that one of the major factors hindering the growth of this market is the vulnerability of EMR toward cybercrime.

Read Full Details

Topics:
  • Business
  • Health
  • Science

Thursday, September 13


News

McKesson Board of Directors Elects Dominic Caruso as New Independent Director

MCK

McKesson Corporation (MCK) today announced that its Board of Directors has elected Dominic Caruso as a new independent director, effective September 12, 2018. “Dominic’s three decades of global financial and operational experience, leadership, and tenure in the healthcare industry make him an ideal addition to our Board of Directors,” said John H. Hammergren, chairman and chief executive officer, McKesson Corporation. “I'm delighted to be joining a company that I've long admired and look forward to adding my perspective and contributing to the company's future development and success,” added Dominic Caruso. Dominic Caruso, age 61, retired as executive vice president and chief financial officer from Johnson & Johnson in August 2018, having served in the role since 2007.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Tuesday, September 11


News

Fort L.P. Purchases New Position in McKesson Co. (MCK) – Marea Informative

MCK

Laurion Capital Management LP decreased its holdings in McKesson Co. (NYSE:MCK) by 45.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). In other news, Director N Anthony Coles sold 1,350 shares of the company’s stock in a transaction on Friday, August 31st. The company reported $2.90 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.89 by $0.01. JPMorgan Chase & Co. dropped their price objective on shares of McKesson from $181.00 to $160.00 and set an “overweight” rating on the stock in a research note on Friday, July 27th.

Read Full Details

Topics:
  • Business
  • Financial

Friday, September 07


News

Mckesson $MCK Technical Update – Stock Traders Daily NEWS

MCK

Our Disruptive Tactical Strategies can work regardless of market direction or economic conditions. September 07, 2018, BY Thomas H. Kee Jr - Editor, Stock Traders Daily | Subscribe to RSS. We have day, swing, and longer-term trading plans for MCK, and 1300 other stocks too, updated in real time for our trial subscribers. The data below is a snapshot, but updates are available now.

Read Full Details

Topics:
  • Business
  • Financial

Monday, August 27


News

As Mckesson Corp (MCK) Market Valuation Declined, Tpg-Axon Management LP Boosted Stake by $4.12 Million

MCK

It is positive, as 73 investors sold MCK shares while 263 reduced holdings. Moreover, Pring Turner Grp has 2.42% invested in McKesson Corporation (NYSE:MCK) for 16,500 shares. Montecito Commercial Bank And Tru holds 0.13% of its portfolio in McKesson Corporation (NYSE:MCK) for 2,798 shares. State Of Wisconsin Invest Board has 0.12% invested in McKesson Corporation (NYSE:MCK). Since March 1, 2018, it had 0 insider purchases, and 2 sales for $334,327 activity.

Read Full Details

Topics:
  • Business
  • Financial
News

Emmaus, a Leader in Sickle Cell Disease Treatment, Signs Agreement with McKesson to Expand Distribution Network for Endari™ (L-glutamine oral powder)

MCK

The agreement makes Endari™ (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older, available nationwide to pharmacies that utilize McKesson as their primary and exclusive distributor. McKesson is the largest healthcare distribution company in the world. Since launching Endari, the first U.S. FDA approved sickle cell treatment in 20 years, Emmaus has brought this therapy to patients in over 30 states, Washington DC and Puerto Rico. “As the demand for Endari continues to increase, we seek to build our distribution network to ensure that we reach patients in need,” said Yutaka Niihara, MD, MPH, CEO and Chairman of Emmaus. About Sickle Cell DiseaseSickle Cell Disease is an inherited blood disorder characterized by the production of an altered form of hemoglobin which polymerizes and becomes fibrous, causing red blood cells to become rigid and change form so that they appear sickle shaped instead of soft and rounded.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial

Thursday, August 23


News

McKesson Corporation to Present at the Morgan Stanley Global Healthcare Conference

MCK

McKesson Corporation (MCK) announced that Britt Vitalone, the company’s executive vice president and chief financial officer, will present at the Morgan Stanley Global Healthcare Conference in New York at 10:30 a.m. McKesson Corporation, currently ranked 6th on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. McKesson has been named the “Most Admired Company” in the healthcare wholesaler category by FORTUNE, a “Best Place to Work” by the Human Rights Campaign Foundation, and a top military-friendly company by Military Friendly. For more information, visit www.mckesson.com.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Monday, August 13


News

Clinical Decision Support Systems: Global Market Opportunities to 2023 featuring Cerner, EPIC, IBM, Mckesson, Meditech, Phillips, and Siemens - ResearchAndMarkets.com

IBM MCK +1 more IBM MCK CERN

DUBLIN--(BUSINESS WIRE)--The "Global Clinical Decision Support Systems Market - Segmented by Model, Mode of Delivery, Component, Product, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering. Clinical decision support systems can give physicians and nurses easy and quick access to drug-specific dosing calculators, full drug profiles with age, weight, disease and renal adjustment dosing, and much more. Owing to these capabilities of the system, there will be a boost in the growth of the clinical decision support systems market. Other factors that will affect the growth of this market include rising demand to reduce healthcare expenditure, need for improvement in quality of care, rising chronic disease population, and more adoption rate in emerging economies.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial